Dolutegravir superior to darunavir at 48 weeks in open-label ART-naive trial
1 October 2013. Related: Conference reports, Antiretrovirals.
Conference reports
7th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 30 June – 3 July 2013, Kuala Lumpur
1 October 2013. Related: Conference reports.
High prices for antiretrovirals in middle-income countries outside Africa
1 October 2013. Related: Conference reports, Antiretrovirals, Treatment access.
Comparable efficacy and pregnancy outcomes with boosted atazanavir and lopinavir at standard doses
1 October 2013. Related: Conference reports, Antiretrovirals, Pregnancy.
PrEP gives little extra benefit in attempted conception if male partner is on ART
1 October 2013. Related: Conference reports, Antiretrovirals, Pregnancy.
7th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 30 June – 3 July 2013, Kuala Lumpur
25 July 2013. Related: Conference reports.
WHO 2013 guidelines: what about the missing formulations?
25 July 2013. Related: Conference reports, Treatment access, Paediatric care, Guidelines.
WHO 2013 guidelines: when the risk:benefit may not favour starting at CD4 count of 500
25 July 2013. Related: Conference reports, Guidelines.
Efavirenz at 400 mg compared to standard 600 mg dose has similar efficacy with fewer side effects
25 July 2013. Related: Conference reports, Antiretrovirals.
Dolutegravir update: drug resistance in people who are treatment-naive and -experienced
25 July 2013. Related: Conference reports, Antiretrovirals, Drug resistance.
Elvitegravir/cobicisat/tenofovir/FTC: Stribild studies at IAS 2013
25 July 2013. Related: Conference reports, Antiretrovirals.
Non-standard combinations: NRTI-sparing combinations
25 July 2013. Related: Conference reports, Antiretrovirals.
ARVs and bone health: the role of NRTIs in second-line therapy
25 July 2013. Related: Conference reports, Side effects.
No viral load rebound off-ART following stem cell transplant: two “cure” cases using reduced intensity conditioning chemotherapy and CCR5 d-32 negative donors
25 July 2013. Related: Conference reports, Cure-related research, Basic science and immunology.
HIV cure research: further capsules at IAS 2013
25 July 2013. Related: Conference reports, Cure-related research, Basic science and immunology.
Partner-dependent immune differences may protect against HIV infection
25 July 2013. Related: Conference reports, HIV prevention and transmission.
Pipeline oral HCV drugs and generic global access to DAAs: the need to mirror ARV programmes
25 July 2013. Related: Conference reports, Treatment access, Hepatitis coinfection.
5th International Workshop on HIV Pediatrics, 28-29 June 2013, Kuala Lumpur
25 July 2013. Related: Conference reports.
Vertical transmission continues to decline in UK and Ireland
25 July 2013. Related: Conference reports, Pregnancy.
Decline in late preterm delivery with vaginal birth in Europe
25 July 2013. Related: Conference reports, Pregnancy.
High loss to follow up among asymptomatic women starting ART in pregnancy in Option B+
25 July 2013. Related: Conference reports, Antiretrovirals, Pregnancy.
Decreased growth in ART exposed uninfected infants in Botswana
25 July 2013. Related: Conference reports, Antiretrovirals, Pregnancy, Paediatric care.
Antiretrovirals, doses and formulations for children
25 July 2013. Related: Conference reports, Antiretrovirals, Paediatric care.
International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies, 4-8 June 2013, Toronto
25 July 2013. Related: Conference reports.
Higher intracellular concentrations with tenofovir alafenamide (TAF) overcomes K65R and other key NRTI resistance in vitro
25 July 2013. Related: Conference reports, Antiretrovirals, Drug resistance.
Tentative phenotypic cut offs for dolutegravir: guidance for use with integrase resistance
25 July 2013. Related: Conference reports, Antiretrovirals, Drug resistance.
S/GSK744 and long-acting formulation indicate broadly similar resistance profile to dolutegravir
25 July 2013. Related: Conference reports, Antiretrovirals, Drug resistance.
One in five people with recent HIV infection in Spain have X4/R5 mixed tropic virus
25 July 2013. Related: Conference reports, Virology.
14th International Workshop on Clinical Pharmacology, 22-24 April 2013, Amsterdam
29 May 2013. Related: Conference reports.
Population pharmacokinetics of efavirenz to inform dosing in children three months of age and above
29 May 2013. Related: Conference reports, Paediatric care, PK and drug interactions.
Bilirubin as a surrogate marker for atazanavir in children
29 May 2013. Related: Conference reports, Paediatric care, PK and drug interactions.
Transplacental transfer of atazanavir and neonatal hyperbilirubinaemia
29 May 2013. Related: Conference reports, Pregnancy, PK and drug interactions.
Tenofovir population pharmacokinetics in pregnancy
29 May 2013. Related: Conference reports, Pregnancy, PK and drug interactions.
Effect of rifampicin on BMS-663068 in HIV negative volunteers
29 May 2013. Related: Conference reports, PK and drug interactions.
Coformulated darunavir/cobicistat: an alternative to separate ritonavir boosting
29 May 2013. Related: Conference reports, PK and drug interactions.
Continuous infusion of T-20 in multidrug resistant patient with intolerance of s.c. injections
29 May 2013. Related: Conference reports, PK and drug interactions.
20th Conference on Retroviruses and Opportunistic Infections (CROI), 3-6 March 2013, Atlanta
29 May 2013. Related: Conference reports.
Small increase in birth defects in the French Perinatal Cohort
29 May 2013. Related: Conference reports, Antiretrovirals, Pregnancy.
Uptake and retention in Malawi’s Option B+ programme
29 May 2013. Related: Conference reports, Antiretrovirals, Pregnancy.
Optimising ART initiation in pregnancy through linkage of services vs integration of ART into antenatal care
29 May 2013. Related: Conference reports, Antiretrovirals, Pregnancy.
Cardiovascular disease and other non-AIDS defining events
29 May 2013. Related: Conference reports, Coinfections and complications.
Dramatic advances at CROI for HCV treatment: telaprevir, boceprevir, faldaprevir, sofosbuvir, ABT-450, ABT-267, ABT-333 and ledipasvir
29 May 2013. Related: Conference reports, Hepatitis coinfection.
Basic research highlights from CROI 2013
29 May 2013. Related: Conference reports, Basic science and immunology.
Probiotic/prebiotic supplement combination shows benefits in SIV-infected pigtailed macaques
29 May 2013. Related: Conference reports, Basic science and immunology.
20th Conference on Retroviruses and Opportunistic Infections (CROI) 3-6 March 2013, Atlanta
1 April 2013. Related: Conference reports.
ARV pipeline: dolutegravir, TAF (GS-7340), MK-1439 and cenicriviroc
1 April 2013. Related: Conference reports, Antiretrovirals.
ARV pipeline: long-acting formulations of rilpivirine, GSK-744 and nanoformulations
1 April 2013. Related: Conference reports, Antiretrovirals.
Five-year results from the AntiRetroviral Research for Watoto (ARROW) Trial
1 April 2013. Related: Conference reports, Antiretrovirals, Paediatric care.
Comparison of ritonavir-boosted lopinavir or NNRTI ART and PK with antimalarials in Ugandan children
1 April 2013. Related: Conference reports, Antiretrovirals, Paediatric care.
Pharmacokinetics and acceptability of lopinavir/ritonavir sprinkles in children aged 1 to 4 years
1 April 2013. Related: Conference reports, Antiretrovirals, Paediatric care, PK and drug interactions.
Pharmacokinetics of currently available antiretroviral options for young children
1 April 2013. Related: Conference reports, Antiretrovirals, Paediatric care, PK and drug interactions.
Safety of transplacental raltegravir in neonates and washout pharmacokinetics
1 April 2013. Related: Conference reports, Antiretrovirals, Pregnancy, PK and drug interactions.
Tenofovir use in children
1 April 2013. Related: Conference reports, Antiretrovirals, Paediatric care.
ddI resistance in South African children failing an abacavir or d4T based first-line regimen
1 April 2013. Related: Conference reports, Antiretrovirals, Paediatric care, Drug resistance.
Statin use in HIV positive people
1 April 2013. Related: Conference reports, Side effects.
RIFAQUIN study demonstrates once-weekly dosing during follow-up phase of TB treatment
1 April 2013. Related: Conference reports, Coinfections and complications, TB coinfection.
Combining Xpert and LAM urine testing improves TB diagnostic sensitivity
1 April 2013. Related: Conference reports, Diagnostics, Coinfections and complications, TB coinfection.
Deferring ART by four weeks reduces mortality in patients diagnosed with cryptococcal meningitis
1 April 2013. Related: Conference reports, Coinfections and complications.
Monthly injection protects macaques from rectal exposure: results should fast-track human studies for advanced PrEP options
1 April 2013. Related: Conference reports, HIV prevention and transmission.
Tenofovir DF ring protects macaques from vaginal exposure
1 April 2013. Related: Conference reports, HIV prevention and transmission.
VOICE study reports low adherence as reason for lack of efficacy for PrEP: anal sex common in African heterosexuals
1 April 2013. Related: Conference reports, HIV prevention and transmission.
Further studies on how male circumcision may reduce HIV transmission
1 April 2013. Related: Conference reports, HIV prevention and transmission.
Report of a functional cure in an HIV infected infant
1 April 2013. Related: Conference reports, Paediatric care, Cure-related research.
3rd International Workshop on HIV and Women, 14-15 January 2013, Toronto
1 February 2013. Related: Conference reports.
Nevirapine-containing ART does not reduce combined oral contraceptive effectiveness
1 February 2013. Related: Conference reports, Antiretrovirals, Women's health.